The FDA's approval is based on results from the Phase III DESTINY-Breast09 trial, in which the combo showed a median 40.7-month progression-free survival.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved additional indications for its PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary ...
The FDA approved T-DXd plus pertuzumab for HER2-positive metastatic breast cancer, based on DESTINY-Breast09 trial results. The combination therapy reduced disease progression or death risk by 44% ...
The Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki, or Enhertu from Daiichi Sankyo (DSNKY), in combination with pertuzumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback